| __timestamp | Halozyme Therapeutics, Inc. | Rhythm Pharmaceuticals, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 35942000 | 1213000 |
| Thursday, January 1, 2015 | 40028000 | 3425000 |
| Friday, January 1, 2016 | 45853000 | 6311000 |
| Sunday, January 1, 2017 | 53816000 | 9518000 |
| Monday, January 1, 2018 | 60804000 | 28080000 |
| Tuesday, January 1, 2019 | 77252000 | 36550000 |
| Wednesday, January 1, 2020 | 45736000 | 46125000 |
| Friday, January 1, 2021 | 50323000 | 68486000 |
| Saturday, January 1, 2022 | 143526000 | 92032000 |
| Sunday, January 1, 2023 | 149182000 | 117532000 |
| Monday, January 1, 2024 | 154335000 |
Unlocking the unknown
In the competitive world of biotechnology, managing operational costs is crucial for success. Halozyme Therapeutics, Inc. and Rhythm Pharmaceuticals, Inc. offer a fascinating study in SG&A (Selling, General, and Administrative) efficiency over the past decade. From 2014 to 2023, Halozyme's SG&A expenses grew by approximately 315%, while Rhythm's expenses skyrocketed by nearly 9,600%. This dramatic increase for Rhythm, especially between 2018 and 2023, reflects its aggressive expansion and investment in administrative capabilities. In contrast, Halozyme's more measured growth suggests a focus on sustainable scaling. By 2023, Halozyme's SG&A expenses reached 149 million, slightly ahead of Rhythm's 118 million, indicating a more controlled expenditure strategy. This comparison highlights the diverse strategies biotech companies employ to balance growth and operational efficiency, offering valuable insights for investors and industry analysts alike.
Biogen Inc. and Rhythm Pharmaceuticals, Inc.: SG&A Spending Patterns Compared
Breaking Down SG&A Expenses: United Therapeutics Corporation vs Rhythm Pharmaceuticals, Inc.
Dr. Reddy's Laboratories Limited or Rhythm Pharmaceuticals, Inc.: Who Manages SG&A Costs Better?
Sarepta Therapeutics, Inc. or Halozyme Therapeutics, Inc.: Who Manages SG&A Costs Better?
Operational Costs Compared: SG&A Analysis of Halozyme Therapeutics, Inc. and Grifols, S.A.
SG&A Efficiency Analysis: Comparing Halozyme Therapeutics, Inc. and Verona Pharma plc
Halozyme Therapeutics, Inc. vs CymaBay Therapeutics, Inc.: SG&A Expense Trends
Comparing SG&A Expenses: Halozyme Therapeutics, Inc. vs Lantheus Holdings, Inc. Trends and Insights
Operational Costs Compared: SG&A Analysis of Halozyme Therapeutics, Inc. and Arrowhead Pharmaceuticals, Inc.
Who Optimizes SG&A Costs Better? Halozyme Therapeutics, Inc. or MannKind Corporation
Comparing SG&A Expenses: Cytokinetics, Incorporated vs Rhythm Pharmaceuticals, Inc. Trends and Insights
Cost Management Insights: SG&A Expenses for ADMA Biologics, Inc. and Rhythm Pharmaceuticals, Inc.